Symbols / PHGE
PHGE Chart
About
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.12M |
| Enterprise Value | 22.82M | Income | -36.20M | Sales | — |
| Book/sh | -12.50 | Cash/sh | 2.74 | Dividend Yield | — |
| Payout | 0.00% | Employees | 20 | IPO | — |
| P/E | — | Forward P/E | -0.34 | PEG | — |
| P/S | — | P/B | -0.36 | P/C | — |
| EV/EBITDA | -0.81 | EV/Sales | — | Quick Ratio | 0.70 |
| Current Ratio | 0.87 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -37.05 | EPS next Y | -12.98 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-25 | ROA | -78.85% |
| ROE | -3.17% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.59M |
| Shs Float | 1.24M | Short Float | 17.96% | Short Ratio | 0.10 |
| Short Interest | — | 52W High | 22.06 | 52W Low | 1.50 |
| Beta | 1.66 | Avg Volume | 1.05M | Volume | 19.87K |
| Target Price | $165.00 | Recom | None | Prev Close | $4.55 |
| Price | $4.47 | Change | -1.76% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$165.00
Mean price target
2. Current target
$4.47
Latest analyst target
3. DCF / Fair value
$-158.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.47
Low
$26.00
High
$304.00
Mean
$165.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-26 | reit | HC Wainwright & Co. | Buy → Buy | $26 |
| 2025-11-25 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2025-08-20 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-05-16 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $21 |
| 2025-04-01 | main | HC Wainwright & Co. | Buy → Buy | $21 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2025-01-08 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-08-16 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-05-28 | init | Laidlaw & Co. | — → Buy | $3 |
| 2024-05-21 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-04-22 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-03-07 | reit | HC Wainwright & Co. | Buy → Buy | $2 |
| 2023-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-08-09 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2023-05-15 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2022-11-10 | main | Chardan Capital | — → Buy | $2 |
| 2022-05-24 | main | Chardan Capital | — → Buy | $6 |
| 2022-05-12 | main | Ladenburg Thalmann | — → Buy | $8 |
- All You Need to Know About BiomX (PHGE) Rating Upgrade to Buy - Yahoo Finance Mon, 29 Dec 2025 08
- BiomX (PHGE) Price Target Increased by 964.52% to 168.30 - Nasdaq Fri, 05 Dec 2025 08
- BiomX (NYSE American: PHGE) halts BX004 CF trial, to cut costs, weigh options - Stock Titan Mon, 08 Dec 2025 08
- BiomX Inc. Announces 1-for-19 Reverse Stock Split - GlobeNewswire Fri, 14 Nov 2025 08
- Why Is BiomX Stock (PHGE) Up 40% Today? - TipRanks Wed, 06 Aug 2025 07
- BiomX stock falls after announcing 1-for-19 reverse split - Investing.com Fri, 14 Nov 2025 08
- BiomX Inc. SEC 10-K Report - TradingView hu, 19 Feb 2026 16
- BiomX Inc (NYSEARCA:PHGE) Surges 142% After Stunning Q2 2025 Earnings Beat and Promising BX211 Phase 2 Results - ChartMill Wed, 13 Aug 2025 07
- BiomX Surges In Pre-Market After Pyu Pyu Capital Discloses 19.99% Stake - Nasdaq ue, 27 Jan 2026 08
- BiomX (NYSE American: PHGE) gets FDA feedback on BX011 in DFI; $40M backing - Stock Titan ue, 04 Nov 2025 08
- BiomX Issues Statement Regarding Recent Common Stock Trading Activity - GlobeNewswire ue, 27 Jan 2026 08
- BiomX stock falls after announcing 1-for-19 reverse split By Investing.com - Investing.com Nigeria Fri, 14 Nov 2025 08
- BiomX Restructures After Insolvency and Executive Terminations - TipRanks ue, 10 Feb 2026 08
- Topline results Q1 2026: BiomX's BX004 Phase 2b on track; FDA offers new development pathways - Stock Titan Fri, 17 Oct 2025 07
- HC Wainwright & Co. Reiterates BiomX (PHGE) Buy Recommendation - Nasdaq Wed, 26 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 126748 | — | — | Stock Award(Grant) at price 0.00 per share. | SOLOMON JONATHAN EITAN | Chief Executive Officer | — | 2025-04-14 00:00:00 | D |
| 1 | 126748 | nan | — | — | SOLOMON JONATHAN EITAN | Chief Executive Officer | — | 2025-04-14 00:00:00 | D |
| 2 | 79597 | — | — | Stock Award(Grant) at price 0.00 per share. | BASSAN MERAV | Officer | — | 2025-04-14 00:00:00 | D |
| 3 | 79597 | nan | — | — | BASSAN MERAV | Officer | — | 2025-04-14 00:00:00 | D |
| 4 | 68545 | — | — | Stock Award(Grant) at price 0.00 per share. | WOLFSON MARINA | Chief Financial Officer | — | 2025-04-14 00:00:00 | D |
| 5 | 68545 | nan | — | — | WOLFSON MARINA | Chief Financial Officer | — | 2025-04-14 00:00:00 | D |
| 6 | 706498 | 657467.0 | — | Conversion of Exercise of derivative security at price 0.93 per share. | FLYNN JAMES E | Director | — | 2025-02-27 00:00:00 | I |
| 7 | 50556 | nan | — | — | SOLOMON JONATHAN EITAN | Chief Executive Officer | — | 2024-09-16 00:00:00 | D |
| 8 | 31749 | nan | — | — | BASSAN MERAV | Officer | — | 2024-09-16 00:00:00 | D |
| 9 | 25804 | nan | — | — | ORON ASSAF | Officer | — | 2024-09-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 103.73K | -17.71K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.23 | 0.23 |
| NormalizedEBITDA | -32.47M | -23.05M | -24.11M | -32.82M |
| TotalUnusualItems | 17.43M | 183.00K | 451.00K | -77.00K |
| TotalUnusualItemsExcludingGoodwill | 17.43M | 183.00K | 451.00K | -77.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -17.73M | -26.17M | -28.32M | -36.23M |
| ReconciledDepreciation | 1.80M | 871.00K | 2.52M | 2.56M |
| EBITDA | -15.04M | -22.87M | -23.66M | -32.90M |
| EBIT | -16.84M | -23.74M | -26.18M | -35.46M |
| NetInterestIncome | -1.74M | -1.34M | -1.62M | -620.00K |
| InterestExpense | 873.00K | 2.40M | 2.07M | 699.00K |
| InterestIncome | 1.05M | 1.12M | 464.00K | 86.00K |
| NormalizedIncome | -35.16M | -26.35M | -28.66M | -36.17M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -17.73M | -26.17M | -28.32M | -36.23M |
| TotalExpenses | 35.55M | 25.35M | 27.22M | 35.46M |
| RentExpenseSupplemental | 593.00K | 298.00K | 346.00K | 291.00K |
| TotalOperatingIncomeAsReported | -44.52M | -25.35M | -27.22M | -35.46M |
| DilutedAverageShares | 691.48K | 270.16K | 157.13K | 136.88K |
| BasicAverageShares | 632.60K | 270.16K | 157.13K | 136.88K |
| DilutedEPS | -27.93 | -96.90 | -180.50 | -264.10 |
| BasicEPS | -27.93 | -96.90 | -180.50 | -264.10 |
| DilutedNIAvailtoComStockholders | -44.19M | -26.17M | -28.32M | -36.23M |
| AverageDilutionEarnings | -26.46M | 0.00 | ||
| NetIncomeCommonStockholders | -17.73M | -26.17M | -28.32M | -36.23M |
| NetIncome | -17.73M | -26.17M | -28.32M | -36.23M |
| NetIncomeIncludingNoncontrollingInterests | -17.73M | -26.17M | -28.32M | -36.23M |
| NetIncomeContinuousOperations | -17.73M | -26.17M | -28.32M | -36.23M |
| TaxProvision | 13.00K | 23.00K | 65.00K | 67.00K |
| PretaxIncome | -17.71M | -26.15M | -28.25M | -36.16M |
| OtherIncomeExpense | 19.57M | 540.00K | 585.00K | -77.00K |
| OtherNonOperatingIncomeExpenses | 2.14M | 357.00K | 134.00K | |
| SpecialIncomeCharges | -8.97M | 0.00 | 0.00 | |
| ImpairmentOfCapitalAssets | 8.08M | 0.00 | ||
| RestructuringAndMergernAcquisition | 888.00K | 0.00 | 0.00 | |
| GainOnSaleOfSecurity | 26.40M | 183.00K | 451.00K | -77.00K |
| NetNonOperatingInterestIncomeExpense | -1.74M | -1.34M | -1.62M | -620.00K |
| TotalOtherFinanceCost | 1.91M | 56.00K | 13.00K | 7.00K |
| InterestExpenseNonOperating | 873.00K | 2.40M | 2.07M | 699.00K |
| InterestIncomeNonOperating | 1.05M | 1.12M | 464.00K | 86.00K |
| OperatingIncome | -35.55M | -25.35M | -27.22M | -35.46M |
| OperatingExpense | 35.55M | 25.35M | 27.22M | 35.46M |
| DepreciationAmortizationDepletionIncomeStatement | 0.00 | 1.52M | 1.52M | |
| DepreciationAndAmortizationInIncomeStatement | 0.00 | 1.52M | 1.52M | |
| Amortization | 0.00 | 1.52M | 1.52M | |
| AmortizationOfIntangiblesIncomeStatement | 0.00 | 1.52M | 1.52M | |
| ResearchAndDevelopment | 24.66M | 16.70M | 16.24M | 22.68M |
| SellingGeneralAndAdministration | 10.89M | 8.65M | 9.46M | 11.27M |
| GeneralAndAdministrativeExpense | 10.89M | 8.65M | 9.46M | 11.27M |
| OtherGandA | 4.57M | 3.37M | 3.20M | 4.12M |
| InsuranceAndClaims | 1.38M | 1.58M | 2.45M | 2.50M |
| RentAndLandingFees | 593.00K | 298.00K | 346.00K | 291.00K |
| SalariesAndWages | 4.35M | 3.40M | 3.46M | 4.36M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | 29.00 | 29.00 | |
| OrdinarySharesNumber | 956.67K | 242.00K | 157.77K | 156.56K |
| ShareIssued | 956.67K | 242.00K | 157.80K | 156.59K |
| TotalDebt | 9.58M | 15.09M | 19.36M | 20.02M |
| TangibleBookValue | -6.55M | 3.08M | 21.04M | 46.02M |
| InvestedCapital | 5.50M | 14.27M | 35.91M | 61.95M |
| WorkingCapital | 12.25M | 6.46M | 28.94M | 55.59M |
| NetTangibleAssets | 12.10M | 3.08M | 21.04M | 46.02M |
| CapitalLeaseObligations | 9.58M | 3.90M | 4.49M | 5.61M |
| CommonStockEquity | 5.50M | 3.08M | 21.04M | 47.53M |
| PreferredStockEquity | 18.64M | |||
| TotalCapitalization | 24.15M | 8.48M | 31.63M | 61.95M |
| TotalEquityGrossMinorityInterest | 24.15M | 3.08M | 21.04M | 47.53M |
| StockholdersEquity | 24.15M | 3.08M | 21.04M | 47.53M |
| RetainedEarnings | -180.70M | -162.97M | -136.80M | -108.48M |
| AdditionalPaidInCapital | 186.19M | 166.05M | 157.84M | 156.02M |
| CapitalStock | 18.65M | 3.00K | 2.00K | 2.00K |
| CommonStock | 6.00K | 3.00K | 2.00K | 2.00K |
| PreferredStock | 18.64M | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 19.09M | 21.95M | 24.49M | 30.45M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 10.82M | 10.77M | 16.55M | 19.41M |
| OtherNonCurrentLiabilities | 77.00K | 155.00K | 188.00K | 215.00K |
| DerivativeProductLiabilities | 2.29M | 0.00 | ||
| NonCurrentDeferredLiabilities | 0.00 | 1.98M | 1.98M | 0.00 |
| NonCurrentDeferredRevenue | 0.00 | 1.98M | 1.98M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 8.45M | 8.64M | 14.39M | 19.20M |
| LongTermCapitalLeaseObligation | 8.45M | 3.24M | 3.80M | 4.79M |
| LongTermDebt | 5.40M | 10.59M | 14.41M | |
| CurrentLiabilities | 8.27M | 11.18M | 7.94M | 11.04M |
| CurrentDeferredLiabilities | 28.00K | 242.00K | 1.98M | |
| CurrentDeferredRevenue | 28.00K | 242.00K | 1.98M | |
| CurrentDebtAndCapitalLeaseObligation | 1.13M | 6.45M | 4.97M | 819.00K |
| CurrentCapitalLeaseObligation | 1.13M | 666.00K | 687.00K | 819.00K |
| CurrentDebt | 5.79M | 4.28M | ||
| OtherCurrentBorrowings | 5.79M | 4.28M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 800.00K | 2.91M | ||
| PayablesAndAccruedExpenses | 7.14M | 4.72M | 2.73M | 8.25M |
| CurrentAccruedExpenses | 3.77M | 1.29M | 887.00K | 2.27M |
| Payables | 3.37M | 3.44M | 1.84M | 5.98M |
| OtherPayable | 1.48M | 2.06M | 1.02M | 3.18M |
| AccountsPayable | 1.88M | 1.38M | 820.00K | 2.79M |
| TotalAssets | 43.23M | 25.03M | 45.53M | 77.99M |
| TotalNonCurrentAssets | 22.71M | 7.40M | 8.65M | 11.35M |
| OtherNonCurrentAssets | 161.00K | |||
| GoodwillAndOtherIntangibleAssets | 12.05M | 0.00 | 0.00 | 1.52M |
| OtherIntangibleAssets | 12.05M | 1.52M | ||
| NetPPE | 10.50M | 7.40M | 8.65M | 9.83M |
| AccumulatedDepreciation | -5.50M | -3.48M | -2.71M | -1.77M |
| GrossPPE | 16.00M | 10.88M | 11.36M | 11.60M |
| Leases | 4.45M | 2.99M | 2.99M | 2.99M |
| OtherProperties | 10.93M | 7.21M | 7.71M | 7.89M |
| MachineryFurnitureEquipment | 620.00K | 679.00K | 666.00K | 721.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 20.52M | 17.63M | 36.88M | 66.64M |
| OtherCurrentAssets | 254.00K | 561.00K | 526.00K | 407.00K |
| RestrictedCash | 958.00K | 957.00K | 962.00K | 996.00K |
| PrepaidAssets | 1.28M | 633.00K | 1.49M | 2.25M |
| Receivables | 1.17M | 574.00K | 567.00K | 888.00K |
| OtherReceivables | 1.17M | 574.00K | 567.00K | 888.00K |
| CashCashEquivalentsAndShortTermInvestments | 16.86M | 14.91M | 33.33M | 62.10M |
| OtherShortTermInvestments | 0.00 | 2.00M | 0.00 | |
| CashAndCashEquivalents | 16.86M | 14.91M | 31.33M | 62.10M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -37.01M | -21.34M | -29.20M | -31.25M |
| RepaymentOfDebt | -10.75M | -4.25M | 0.00 | |
| IssuanceOfDebt | 0.00 | 14.22M | ||
| IssuanceOfCapitalStock | 21.29M | 7.49M | 273.00K | 22.93M |
| CapitalExpenditure | -30.00K | -50.00K | -112.00K | -3.68M |
| InterestPaidSupplementalData | 1.44M | 1.87M | 1.55M | 67.00K |
| IncomeTaxPaidSupplementalData | 13.00K | 54.00K | 65.00K | 399.00K |
| EndCashPosition | 17.98M | 15.86M | 32.29M | 63.09M |
| BeginningCashPosition | 15.86M | 32.29M | 63.09M | 37.24M |
| EffectOfExchangeRateChanges | 1.00K | 6.00K | 106.00K | -25.00K |
| ChangesInCash | 2.11M | -16.44M | -30.91M | 25.88M |
| FinancingCashFlow | 38.37M | 2.90M | 292.00K | 37.28M |
| CashFlowFromContinuingFinancingActivities | 38.37M | 2.90M | 292.00K | 37.28M |
| NetOtherFinancingCharges | -918.00K | -333.00K | 19.00K | |
| ProceedsFromStockOptionExercised | 28.75M | 0.00 | 0.00 | 130.00K |
| NetPreferredStockIssuance | 21.27M | 0.00 | ||
| PreferredStockIssuance | 21.27M | 0.00 | ||
| NetCommonStockIssuance | 19.00K | 7.49M | 273.00K | 22.93M |
| CommonStockIssuance | 19.00K | 7.49M | 273.00K | 22.93M |
| NetIssuancePaymentsOfDebt | -10.75M | -4.25M | 0.00 | 14.22M |
| NetLongTermDebtIssuance | -10.75M | -4.25M | 0.00 | 14.22M |
| LongTermDebtPayments | -10.75M | -4.25M | 0.00 | |
| LongTermDebtIssuance | 0.00 | 14.22M | ||
| InvestingCashFlow | 715.00K | 1.95M | -2.11M | 16.17M |
| CashFlowFromContinuingInvestingActivities | 715.00K | 1.95M | -2.11M | 16.17M |
| NetInvestmentPurchaseAndSale | 0.00 | 2.00M | -2.00M | 19.85M |
| SaleOfInvestment | 0.00 | 2.00M | 11.50M | 19.85M |
| PurchaseOfInvestment | 0.00 | -13.50M | 0.00 | |
| NetBusinessPurchaseAndSale | 663.00K | 0.00 | ||
| SaleOfBusiness | 663.00K | 0.00 | ||
| NetPPEPurchaseAndSale | 52.00K | -49.00K | -107.00K | -3.68M |
| SaleOfPPE | 82.00K | 1.00K | 5.00K | 4.00K |
| PurchaseOfPPE | -30.00K | -50.00K | -112.00K | -3.68M |
| OperatingCashFlow | -36.98M | -21.29M | -29.09M | -27.57M |
| CashFlowFromContinuingOperatingActivities | -36.98M | -21.29M | -29.09M | -27.57M |
| ChangeInWorkingCapital | -2.99M | 2.48M | -4.43M | 3.10M |
| ChangeInOtherWorkingCapital | 316.00K | -93.00K | -106.00K | 1.98M |
| ChangeInOtherCurrentLiabilities | 2.00K | |||
| ChangeInOtherCurrentAssets | 842.00K | 819.00K | 956.00K | 33.00K |
| ChangeInPayablesAndAccruedExpense | -4.15M | 1.75M | -5.28M | 1.09M |
| ChangeInPayable | -4.15M | 1.75M | -5.28M | 1.09M |
| ChangeInAccountPayable | -3.17M | 556.00K | -1.98M | 427.00K |
| OtherNonCashItems | -2.49M | 406.00K | -396.00K | -252.00K |
| StockBasedCompensation | 1.85M | 1.06M | 1.53M | 3.24M |
| AssetImpairmentCharge | 8.08M | 0.00 | ||
| DepreciationAmortizationDepletion | 1.80M | 871.00K | 2.52M | 2.56M |
| DepreciationAndAmortization | 1.80M | 871.00K | 2.52M | 2.56M |
| AmortizationCashFlow | 1.52M | 1.52M | ||
| AmortizationOfIntangibles | 1.52M | 1.52M | ||
| Depreciation | 1.80M | 871.00K | 1.00M | 1.05M |
| OperatingGainsLosses | -25.50M | 71.00K | 24.00K | |
| GainLossOnInvestmentSecurities | -25.73M | |||
| GainLossOnSaleOfPPE | 221.00K | 71.00K | 24.00K | |
| NetIncomeFromContinuingOperations | -17.73M | -26.17M | -28.32M | -36.23M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PHGE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|